Review: Neutralizing antibodies against interferon-beta

by Per Soelberg Sorensen
Published 2008-09-01

Pulsed immune reconstitution therapy in multiple sclerosis

by Per Soelberg Sorensen, Finn Sellebjerg
Published 2019-03-01

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects

by Per Soelberg Sorensen, Morten Blinkenberg
Published 2016-01-01

Comorbidity in Multiple Sclerosis

by Melinda Magyari, Melinda Magyari, Per Soelberg Sorensen
Published 2020-08-01

Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis

by Per Soelberg Sørensen, Wiendl, Andreas Lysandropoulos, Andrew Chan
Published 2016-07-01

Major depressive disorder and subthreshold depression in prepubertal children from the Danish National Birth Cohort

by Rikke Wesselhoeft, Einar R. Heiervang, Per Kragh-Sørensen, Merete Juul Sørensen, Niels Bilenberg
Published 2016-10-01

Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China

by Yinghao Sun, Liping Xie, Tao Xu, Jørn S. Jakobsen, Weiqing Han, Per S. Sørensen, Xiaofeng Wang
Published 2020-07-01

Correction: Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression.

by Jeppe Romme Christensen, Lars Börnsen, Rikke Ratzer, Fredrik Piehl, Mohsen Khademi, Tomas Olsson, Per Soelberg Sørensen, Finn Sellebjerg
Published 2013-01-01

Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.

by Jeppe Romme Christensen, Lars Börnsen, Rikke Ratzer, Fredrik Piehl, Mohsen Khademi, Tomas Olsson, Per Soelberg Sørensen, Finn Sellebjerg
Published 2013-01-01

Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.

by Finn Sellebjerg, Martin Krakauer, Signe Limborg, Dan Hesse, Henrik Lund, Annika Langkilde, Helle Bach Søndergaard, Per Soelberg Sørensen
Published 2012-01-01

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.

by Lars Börnsen, Jeppe Romme Christensen, Rikke Ratzer, Annette Bang Oturai, Per Soelberg Sørensen, Helle Bach Søndergaard, Finn Sellebjerg
Published 2012-01-01

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study

by Giancarlo Comi, Stuart Cook, Kottil Rammohan, Per Soelberg Sorensen, Patrick Vermersch, Abidemi K. Adeniji, Fernando Dangond, Gavin Giovannoni
Published 2018-01-01

Multiple sclerosis impairs regional functional connectivity in the cerebellum

by Anne-Marie Dogonowski, Kasper Winther Andersen, Kristoffer Hougaard Madsen, Per Soelberg Sørensen, Olaf Bjarne Paulson, Morten Blinkenberg, Hartwig Roman Siebner
Published 2014-01-01

Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review

by Óscar Fernández, Óscar Fernández, Per Soelberg Sörensen, Per Soelberg Sörensen, Giancarlo Comi, Giancarlo Comi, Patrick Vermersch, Hans-Peter Hartung, Hans-Peter Hartung, Hans-Peter Hartung, Letizia Leocani, Letizia Leocani, Thomas Berger, Thomas Berger, Bart Van Wijmeersch, Bart Van Wijmeersch, Celia Oreja-Guevara, Celia Oreja-Guevara
Published 2024-04-01

Expert opinion on the use of cladribine tablets in clinical practice

by Per Soelberg Sørensen, Diego Centonze, Gavin Giovannoni, Xavier Montalban, Daniel Selchen, Patrick Vermersch, Heinz Wiendl, Bassem Yamout, Hashem Salloukh, Peter Rieckmann
Published 2020-06-01

Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.

by Lars Börnsen, Jeppe Romme Christensen, Rikke Ratzer, Chris Hedegaard, Helle B Søndergaard, Martin Krakauer, Dan Hesse, Claus H Nielsen, Per S Sorensen, Finn Sellebjerg
Published 2015-01-01

Secondary progressive and relapsing remitting multiple sclerosis leads to motor-related decreased anatomical connectivity.

by Mark Lyksborg, Hartwig R Siebner, Per S Sørensen, Morten Blinkenberg, Geoff J M Parker, Anne-Marie Dogonowski, Ellen Garde, Rasmus Larsen, Tim B Dyrby
Published 2014-01-01

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice

by Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H. Hua, Celia Oreja-Guevara, Daniel Selchen, Per Soelberg Sørensen, Patrick Vermersch, Heinz Wiendl, Hashem Salloukh, Bassem Yamout
Published 2021-12-01

Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review

by Isa Ahmed AlSharoqi, Mohamed Aljumah, Saeed Bohlega, Cavit Boz, Abdelkader Daif, Salam El-Koussa, Jihad Inshasi, Murat Kurtuncu, Thomas Müller, Chris Retief, Mohammad Ali Sahraian, Vahid Shaygannejad, Ilham Slassi, Karim Taha, Magd Zakaria, Per Soelberg Sørensen
Published 2020-04-01

Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network

by Jan Hillert, Melinda Magyari, Melinda Magyari, Per Soelberg Sørensen, Helmut Butzkueven, Helmut Butzkueven, Anneke Van Der Welt, Sandra Vukusic, Sandra Vukusic, Sandra Vukusic, Maria Trojano, Pietro Iaffaldano, Fabio Pellegrini, Robert Hyde, Leszek Stawiarz, Ali Manouchehrinia, Tim Spelman, Tim Spelman
Published 2021-03-01